FDA Approves Jentadueto™ (Linagliptin/metformin Hydrochloride) Tablets for the Treatment of Adults With Type 2 Diabetes official

For Non-US and Non-UK Media Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) have announced that the US Food and Drug Administration (FDA) has approved Jentadueto™ (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.1 Linagliptin/metformin hydrochloride (HCl) provides a new, single-tablet treatment option, taken twice-d
Powered by NewsLook.com
Producer : Business Wire